1. Targeting IL-23 for Therapeutic Longevity in Psoriasis

3. Activity Components

4. An Introduction to the Immunopathogenesis of Psoriasis and Rationale for Targeted Biologics: Why Target IL-23?

5. Key Cytokines Involved in Psoriasis Pathogenesis

6. Consequences of IL-23 Specific Inhibition

7. IL-23 as a Master Switch in Psoriasis

8. Summary

9. IL-23 Inhibitors for Biologic-Naive Psoriasis Patients

10. IL-23 Inhibitors in Moderate to Severe Psoriasis -- Approved and in Latest Development Stages

11. Guselkumab vs Adalimumab: VOYAGE-1 and VOYAGE-2

12. Guselkumab vs Secukinumab: ECLIPSE

13. Tildrakizumab vs Etanercept: reSURFACE-1 and reSURFACE-2

14. Risankizumab vs Ustekinumab -- ultIMMA and Risankizumab vs Adalimumab -- IMMvent

15. Mirikizumab: PASI 90 at Week 16 Phase 2 Study

16. Ranking of IL-23p19 Inhibitors -- Expert Perspective

17. IL-23p19 Inhibitors -- Insights on Remission and Disease-Modifying Effect

18. Summary

19. IL-23 Inhibitors for Biologic-Experienced Psoriasis Patients

20. Advantages of IL-23p19 Inhibitors

21. IL-23 Inhibitors in PsA

22. Advantages of IL-23p19 Inhibitors (cont)

23. Safety: IL-17 and IL-23p19 Inhibitors

24. Summary

25. IL-23 Inhibitors: Where They Fit in the Treatment Paradigm and Their Impact on Clinical Practice

26. Patient-Based Approach to Care

27. Secukinumab After Anti-TNF-α Failure

28. Long-Term Responses From Guselkumab vs Secukinumab in the ECLIPSE Trial

29. Patient-Specific Factors When Choosing IL-23 Antagonist Therapy

30. Summary

31. Abbreviations